Setogepram

DB15447InvestigationalSmall molecule

Setogepram is under investigation in clinical trial NCT03184584 (Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome).

Mechanism: Pharmacologically active on G protein-coupled receptor 84 and Free fatty acid receptor 1
Curator reviewed
Formula / weight: C₁₃H₁₈O₂ · 206.285 g/mol (avg)
Also known as: 2-(3-Pentylphenyl)acetic acid · 3-Pentylbenzenacetic acid · Fezagepras
Code names: PBI-4050

Resolves to

Compound

Structure

InChIKeyPEGQOIGYZLJMIB-UHFFFAOYSA-NSMILESCCCCCC1=CC(CC(O)=O)=CC=C1

Targets

What you can answer from here — as of August 30, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Setogepram, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.